60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

In 60 Degrees Pharmaceuticals’ expanded-access study of relapsing babesiosis, all five patients who completed tafenoquine-containing treatment reported being much or very much improved and tested negative for Babesia by conventional PCR. Four of the five also tested negative on highly sensitive post-treatment NAT testing; two additional patients remain on treatment, bringing enrollment to seven. The study remains open pending potential discussions with the FDA.

Analysis

The update modestly improves the clinical plausibility of tafenoquine-containing retreatment, but it is not yet evidence of a reproducible treatment effect: five patients completed treatment, there is no comparator, and symptom improvement is patient-reported. The gap between conventional PCR and the more sensitive NAT result in one patient is particularly relevant in immunosuppressed patients, where residual infection or relapse risk could matter more than short-term symptom response. Durability of follow-up is therefore more decision-useful than the initial response rate.

For SXTP, the near-term mechanism is event-driven sentiment and increased visibility, not a demonstrated change in revenue or valuation fundamentals. Any value uplift depends on FDA engagement translating into a defined development path, adequate enrollment, and durable, sensitive-test-confirmed outcomes. Expanded access results may not establish the evidence needed for approval. The study remains small and open, so additional patients could materially change the apparent signal.

Over days, the headline may attract speculative buying; in the next 1–3 months, FDA feedback and follow-up data are the key catalysts. Over 6–18 months, trial design, funding capacity, and regulatory requirements determine whether the result becomes an investable asset. The contrarian point is that optimistic wording can obscure the distinction between conventional PCR clearance and highly sensitive NAT negativity. No trade is warranted on this release alone; treat SXTP as a high-risk clinical catalyst watch, not a validated efficacy story.

Key Decisions for Investors

• Do not chase an immediate SXTP move solely on this small, uncontrolled update; reassess after price action and any company-provided follow-up.
• Watch for FDA feedback, study expansion or protocol details, duration of follow-up, and outcomes on sensitive NAT testing; these are more informative than another short-term symptom-response percentage.
• Before underwriting a position, verify cash runway, financing needs, and whether the company has outlined a controlled development plan. No funding or valuation conclusion is supported by this release.
• Falsification trigger: subsequent patients show persistent or recurrent infection on sensitive testing, or FDA feedback requires a materially larger or longer study than the company can support.